KR102578087B1 - 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법 - Google Patents

숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법 Download PDF

Info

Publication number
KR102578087B1
KR102578087B1 KR1020207007328A KR20207007328A KR102578087B1 KR 102578087 B1 KR102578087 B1 KR 102578087B1 KR 1020207007328 A KR1020207007328 A KR 1020207007328A KR 20207007328 A KR20207007328 A KR 20207007328A KR 102578087 B1 KR102578087 B1 KR 102578087B1
Authority
KR
South Korea
Prior art keywords
protein
galectin
matrix
poi
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007328A
Other languages
English (en)
Korean (ko)
Other versions
KR20200037396A (ko
Inventor
리사 에이 코넬-크라울리
메간 제이. 머클루어
로널드 오. 길레스피
Original Assignee
저스트-에보텍 바이오로직스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 저스트-에보텍 바이오로직스, 아이엔씨. filed Critical 저스트-에보텍 바이오로직스, 아이엔씨.
Publication of KR20200037396A publication Critical patent/KR20200037396A/ko
Application granted granted Critical
Publication of KR102578087B1 publication Critical patent/KR102578087B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207007328A 2017-08-17 2018-08-17 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법 Active KR102578087B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546558P 2017-08-17 2017-08-17
US62/546,558 2017-08-17
PCT/US2018/046919 WO2019036626A1 (en) 2017-08-17 2018-08-17 PROCESS FOR PURIFYING GLYCOSYLATED PROTEIN FROM GALECTINES AND OTHER HOST CELL CONTAMINANTS

Publications (2)

Publication Number Publication Date
KR20200037396A KR20200037396A (ko) 2020-04-08
KR102578087B1 true KR102578087B1 (ko) 2023-09-18

Family

ID=63684424

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007328A Active KR102578087B1 (ko) 2017-08-17 2018-08-17 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법

Country Status (10)

Country Link
US (1) US11358983B2 (https=)
EP (1) EP3668985B1 (https=)
JP (1) JP7097433B2 (https=)
KR (1) KR102578087B1 (https=)
CN (1) CN111344410B (https=)
CA (1) CA3067735A1 (https=)
DK (1) DK3668985T3 (https=)
ES (1) ES2887046T3 (https=)
MY (1) MY199833A (https=)
WO (1) WO2019036626A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3668985T3 (da) 2017-08-17 2021-09-20 Just Evotec Biologics Inc Fremgangsmåde til rensning af glycosyleret protein fra værtscellegalectiner og andre urenheder
US11180540B2 (en) * 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
WO2023192926A2 (en) * 2022-03-30 2023-10-05 Ionis Pharmaceuticals, Inc. Methods for separating certain oligonucleotide compounds
TW202502843A (zh) * 2023-03-17 2025-01-16 日商丸善石油化學股份有限公司 聚合物之製造方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990001063A1 (en) 1988-07-23 1990-02-08 Delta Biotechnology Limited New secretory leader sequences
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AT403989B (de) 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
EP0950067B1 (en) 1996-11-27 2007-08-29 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2350226C (en) 1998-11-20 2012-04-24 Fuso Pharmaceutical Industries, Ltd. Protein expression vector and utilization thereof
JP2002538841A (ja) 1999-03-18 2002-11-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２７個のヒト分泌タンパク質
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
DE602004026343D1 (de) 2003-10-24 2010-05-12 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
TWI372763B (en) * 2005-06-17 2012-09-21 Wyeth Llc Methods of purifying anti a beta antibodies
FR2894146B1 (fr) 2005-12-07 2008-06-06 Ifremer Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus a des fins d'ingenierie des tissus conjonctifs non mineralises
WO2007109163A2 (en) 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
AU2008206923A1 (en) 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of Fc-containing proteins
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
EP2321338A1 (en) 2008-08-14 2011-05-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
WO2011038894A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
ES2813398T3 (es) * 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
EP2513134B1 (en) 2009-12-18 2017-09-06 Novartis AG Wash solution and method for affinity chromatography
CN103429609A (zh) 2010-12-08 2013-12-04 安姆根有限公司 在氨基酸存在下的离子交换层析
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
AU2015273049B2 (en) * 2014-06-13 2019-11-14 Lupin Limited Process for the purification of TNFR:Fc fusion protein
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
AU2016261854B2 (en) 2015-05-12 2022-05-26 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
CN106749660B (zh) * 2016-12-27 2020-02-14 嘉和生物药业有限公司 单克隆抗体下游纯化过程中有效去除宿主蛋白的方法
DK3668985T3 (da) 2017-08-17 2021-09-20 Just Evotec Biologics Inc Fremgangsmåde til rensning af glycosyleret protein fra værtscellegalectiner og andre urenheder
JP2022520793A (ja) * 2019-02-15 2022-04-01 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 自動バイオ製造システム、施設、及びプロセス

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Joucla, G., et al., Journal of Chromatography B, 2013, vol. 942, pp. 126-133

Also Published As

Publication number Publication date
EP3668985B1 (en) 2021-06-16
JP2020531411A (ja) 2020-11-05
US20210163528A1 (en) 2021-06-03
JP7097433B2 (ja) 2022-07-07
WO2019036626A1 (en) 2019-02-21
ES2887046T3 (es) 2021-12-21
KR20200037396A (ko) 2020-04-08
US11358983B2 (en) 2022-06-14
CN111344410B (zh) 2023-09-15
MY199833A (en) 2023-11-24
EP3668985A1 (en) 2020-06-24
CA3067735A1 (en) 2019-02-21
DK3668985T3 (da) 2021-09-20
CN111344410A (zh) 2020-06-26

Similar Documents

Publication Publication Date Title
JP6979442B2 (ja) オーバーロード／溶出クロマトグラフィー
KR102578087B1 (ko) 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법
KR101370253B1 (ko) 재조합 항체의 재접힘 방법
CA2917097C (en) Antibody formulations and methods
CA2976623C (en) Fc fusion high affinity ige receptor .alpha.-chain
KR20200089282A (ko) 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
KR20220154097A (ko) 다중특이적 항체, 이를 포함하는 조성물, 그의 벡터 및 용도
TW202112799A (zh) 過載層析管柱之再生方法
JP7812826B2 (ja) 生物活性が低下した抗体バリアント
HK40027581B (zh) 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
HK40027581A (en) Method of purifying glycosylated protein from host cell galectins and other contaminants
RU2820588C2 (ru) Способы очистки гетеродимерных полиспецифических антител
CN116327963B (zh) 一种眼科制剂及其用途
RU2793783C1 (ru) Способы и композиции, включающие очищенные рекомбинантные полипептиды
HK40114848A (zh) 具有降低的生物活性的抗体变体和同种型
TW202309062A (zh) 抗體組成物之純化方法
HK40061242A (en) A method for regeneration of an overload chromatography column
HK40108969A (zh) 生物学活性降低的抗体变体
HK40005408A (en) Antibody purification method
HK40022824A (en) Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
HK40031063B (zh) 具有降低的生物活性的抗体变体和同种型
HK40008360A (en) Aflibercept formulations and uses thereof
HK40008360B (en) Aflibercept formulations and uses thereof
HK1170633A (en) Concentrated polypeptide formulations with reduced viscosity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4